Trial
NCT02410499
Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Takeda
Collaborators
—
Condition
Diabetic Nephropathy
Intervention
MLN1202 Placebo
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-09-25